12 results
To study the effect of oral pretreatment with dipyridamole on troponin-I release after CABG. Secondary objectives are whether oral pretreatment with dipyridamole reduces postoperative CABG arrhythmias, prolonged inotropic support, and duration of…
Primary objective: The primary objective of the study is to determine the effect of oral dipyridamole treatment on the innate immune response induced by a lipopolysaccharide (LPS) challenge. Various pro- and anti-inflammatory cytokines will be…
1. Creating a reproducible and valid method for adenosine measurement2. Studying the effect of dipyridamole on the endogenous adenosine concentration before and after CPT.
Explore 4 week post-treatment effect of seven day administration of dipyridamole on nucleoside transport inhibition.
To test the hypothesis that dipyridamole improves tolerance to ischemia-reperfusion in patients undergoing elective PCI.
The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.
The purpose of this project is to explore whether a short treatment with dipyridamole (2.5 days; i.e. 5 capsules) can reduce ischemia-reperfusion injury in the forearm.
Creating a reproducible and valid method for adenosine measurement
To study whether dipyridamole reduces gastrointestinal absorption of metformin.
Primary objectives: Part I: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake. Part II: 89Zr-GC1008 PET imaging in patients with…
Objecive of phase I was the determination of the maximum tolerated dose (MTD) and recommended phase II dose of BI836845 in combination with exemestane and everolimus in women with HR+ / HER2- locally advanced or metastatic breast cancer.Ojective of…
Primary Objective: to obtain reliable estimates of the rates of vascular death and non-fatal stroke in patients with atrial fibrillation and a recent anticoagulation-associated ICH who are treated with apixaban versus those who are treated with APDs…